Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Retatrutide is an investigational weight loss medication and is not FDA-approved at this time
Tirzepatide operates as a dual GIP/GLP-1 receptor agonist, while semaglutide targets only GLP-1
B12 injections are elective wellness services and are not intended to diagnose, treat, cure, or prevent disease
Annual thyroid function testing may be prudent given theoretical thyroid concerns, though risk appears minimal in humans
But just as weight loss was initially a byproduct of using GLP-1s for diabetes treatment, these side effects may not be side effects at all, but the cause of the weight loss
Non-GLP-1 prescription options like Qsymia and Contrave remain available for those who don't respond to or tolerate GLP-1 drugs
US$ 26.71
US$ 20.80
US$ 27.22
US$ 29.82
